Blanket Purchase Agreement 36F79722D0178-36E79722A0024
Award Date
9/1/22
Last Date to Order
8/31/25
Federal Agency
National Acquisition Center
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This federal contract IDV award to Glaxosmithkline, LLC from the Department of Veterans Affairs (VA) National Acquisition Center procures influenza vaccines for use by the VA, Bureau of Prisons (BOP), Indian Health Service (IHS), and Captain James A. Lovell Federal Health Care Center. The contract has a total estimated annual usage of 306,829 vaccine doses across various product types including 10-dose vials, pre-filled pediatric syringes, and pre-filled syringes for adults 36 months and...
This federal contract IDV award is a multiple award Federal Supply Schedule contract held by Glaxosmithkline, LLC, a pharmaceutical company that provides a range of vaccines, antiviral medications, and other pharmaceutical products to various U.S. government agencies. The contract covers pharmaceutical products and medical supplies in FSC 65 IB, with a maximum ceiling value of $3.9 billion and a period of performance through July 2027.
The IDV has generated numerous delivery orders for...
The federal contract IDV award SPE2DP18D0006 is a single-award indefinite delivery contract issued by the U.S. Department of Defense (DoD) Medical Supply Chain to the pharmaceutical company Glaxosmithkline, LLC. The contract, valued at a ceiling of $27,848,725.95, enables the DoD to order influenza virus vaccines and other pharmaceutical products from Glaxosmithkline, a foreign-owned for-profit organization, over the term of the agreement.
Task orders issued under the IDV provide for the firm...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Grifols USA LLC, a for-profit manufacturer of pharmaceutical goods. The $107.5 million BPA is for the provision of PROLASTIN-C, an alpha1-proteinase inhibitor used to treat alpha1-antitrypsin deficiency.
This IDV contract allows federal agencies, particularly the VA, Department of Justice's Bureau of Prisons, and...
The federal contract IDV award is a $13,916,000 Indefinite Delivery Contract issued by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC to provide adult influenza vaccines for the 2025-2026 season. The contract has a period of performance through February 28, 2026.
GlaxoSmithKline, a pharmaceutical company that supplies vaccines and other products to federal agencies, will deliver the seasonal flu vaccines under this multiple award IDV contract. The contract...
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The FSS contract, under Federal Supply Class 65 I B, provides for the delivery of pharmaceutical and hematology-related products to VA facilities nationwide, with a ceiling value of $225,000 and a period of performance through May 2028.
Additionally, Nobelpharma America, LLC was...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Alvogen, Inc., a for-profit manufacturer of pharmaceutical and healthcare products. The contract, valued at $32,885,990.00, is for the provision of pharmaceuticals, drugs, and hematology-related products (FSS-61-IB) to the VA and other federal agencies.
The contract has an ultimate completion date of September 1, 2025 and was originally awarded on April 15, 2017. It...
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule, with a ceiling value of $2,210,000,000 and a period of performance through September 2026.
Biogen has been awarded multiple firm-fixed-price delivery orders against this FSS contract for the supply of specialized...
The federal contract indefinite delivery vehicle (IDV) award V797D70252 is a multiple-award Federal Supply Schedule (FSS) contract held by Gilead Sciences Inc. (Gilead) under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract has a ceiling value of $5.5 billion and an ultimate completion date of September 29, 2025.
Gilead, a prominent biopharmaceutical company, provides a range of critical pharmaceutical products to the U.S. Department of Veterans Affairs (VA) and other federal...
The federal contract IDV award is a $1.38 billion Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with Grifols USA LLC, a global healthcare company specializing in plasma-derived medicines and pharmaceutical supplies. Under this IDV, Grifols holds a $107.5 million Blanket Purchase Agreement specifically for the supply of PROLASTIN-C, an alpha1-proteinase inhibitor drug used to treat alpha1-antitrypsin deficiency. Grifols...